Search clinical trials for: Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949

Total 1520 results

University of Southern California
National Cancer Institute (NCI)

Terminated

CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | Locally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm

United States
Bio-Thera Solutions

Active, not recruiting

Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumor Patients in China

Advanced Solid Tumors

China
Shanghai Henlius Biotech

Not yet recruiting

Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HLX51 in Patients With Solid Tumor or Lymphoma

Solid Tumor, Adult Lymphoma
Kymab Limited
Sanofi

Completed

Study Testing Response Effect of KY1005 Against Moderate-to-Severe Atopic Dermatitis, The STREAM-AD Study (STREAM-AD)

Eczema | Atopic Dermatitis

United States, Australia, Bulgaria, Canada, Czechia, Germany, Hungary, Japan, Poland, Spain, Taiwan, United Kingdom
Genentech, Inc.

Completed

A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors

Neoplasms

United States, Spain, Belgium, Korea, Republic of, Canada, Australia, France
Providence Health & Services
MedImmune LLC

Terminated

Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer

Colorectal Neoplasms

United States
Providence Health & Services
MedImmune LLC

Completed

Anti-OX40 Antibody in Head and Neck Cancer Patients

Head and Neck Cancer

United States
Institute of Hematology & Blood Diseases Hospital...
Henan Cancer Hospital; Beijing Children's Hospital; Tianjin Medical University... and other collaborators

Recruiting

TPO-RAs Combining Anti-CD 20 Monoclonal Antibody Versus TPO-RAs in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)

Primary Immune Thrombocytopenia (ITP)

China
Bio-Thera Solutions

Terminated

Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumour Patients

Advanced Solid Tumour

Australia
Ronald Levy
Bristol-Myers Squibb

Completed

SD-101 and BMS-986178 in Treating Patients With Advanced or Metastatic Solid Malignancies

Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Extracranial Solid Neoplasm

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

Recurrent Colon Carcinoma | Recurrent Rectal Carcinoma | Rectal Adenocarcinoma | Colon Adenocarcinoma | ERBB2 Gene Amplification | Stage III Colon Cancer AJCC v7 | Stage III Rectal Cancer AJCC v7 | Stage IIIA Colon Cancer AJCC v7 | Stage IIIA Rectal Cancer AJCC v7 | Stage IIIB Colon Cancer AJCC v7 | Stage... and other conditions

United States, Puerto Rico
Inhibrx, Inc.

Recruiting

INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

Head and Neck Squamous Cell Carcinoma (HNSCC)

United States
George W. Sledge Jr.
National Cancer Institute (NCI)

Completed

4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | HER2 Positive Breast Carcinoma | Stage III Breast Cancer

United States
Biotech Pharmaceutical Co., Ltd.

Terminated

Tolerability, Safety and Pharmacokinetic Study of Humanized Anti-CD6 Monoclonal Antibody Injection in Chinese Psoriasis

Psoriasis

China
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer

Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | HER2 Positive Breast Carcinoma

United States
Henlix, Inc

Terminated

A Study of HLX06, a Humanized Monoclonal Antibody Targeting Human Vascular Endothelial Growth Factor Receptor-2 in Patients With Advanced Solid Tumors

Solid Tumor, Adult

Taiwan
National Institute of Dental and Craniofacial Research...

Terminated

Pilot Study of Raptiva to Treat Sjogren's Syndrome

Sjogren's Syndrome

United States
Shanghai Henlius Biotech

Completed

A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HLX26 Monoclonal Antibody Injection in Patients With Solid Tumor or Lymphoma

Lymphoma | Solid Tumor, Adult

China
University of Arizona
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy in Treating Patients With Advanced Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous/Nonmalignant Condition

United States
University of Arizona
National Cancer Institute (NCI)

Completed

Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma

Head and Neck Cancer | Recurrent Head and Neck Squamous Cell Carcinoma | Oropharyngeal Cancer | HNSCC | Recurrent Oropharyngeal Squamous Cell Carcinoma | Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma | Stage IVA Nasal Cavity and... and other conditions

United States
Lanzhou Institute of Biological Products Co., Ltd

Recruiting

Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL

Lymphoma, Non-Hodgkin | Lymphoma, T-Cell

China
HuniLife Biotechnology, Inc.

Recruiting

A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Immunogenicity of HuL001

Idiopathic Pulmonary Fibrosis

Taiwan
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin Pharma, Inc.

Terminated

Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma

Multiple Myeloma

United States
Henlix, Inc

Unknown

Phase 1 Study of HLX10, a Monoclonal Antibody Targeting Programmed Death-1 (PD-1) in Patients With Advanced Solid Tumors

Solid Tumor

Taiwan
National Cancer Institute (NCI)

Terminated

Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer

Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer

United States
Sinocelltech Ltd.

Unknown

SCT200 Plus Platinum-based Chemotherapy in Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma

China
Novartis Pharmaceuticals

Completed

A Phase I Study of LFA102 in Japanese Patients

Castration-resistant Prostate Cancer, Advanced Breast Cancer

Japan
PanGenetics UK Limited

Terminated

Single Dose PG102 in Patients With Active Psoriatic Arthritis

Arthritis, Psoriatic

Serbia
Ahmad Tarhini
Pfizer

Completed

Safety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV Melanoma

Melanoma

United States
Northwestern University
National Cancer Institute (NCI); Pfizer

Terminated

Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | HER2/Neu Positive | Progesterone Receptor Negative | Breast Carcinoma Metastatic in the Brain

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Adenocarcinoma | Stage III Uterine Corpus Cancer AJCC v7 | Stage IV Uterine Corpus Cancer AJCC v7 | ERBB2 Gene Amplification

United States
Biocad

Active, not recruiting

Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial Spondyloarthritis (ELEFTA)

Axial Spondyloarthritis

Russian Federation
Northwestern University

Completed

Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas

Neurofibromatosis Type 1 | Neurofibromatosis Type 2 | Adult Ependymoma | Recurrent Adult Brain Tumor | Acoustic Schwannoma | Adult Anaplastic Meningioma | Adult Grade I Meningioma | Adult Grade II Meningioma | Adult Meningeal Hemangiopericytoma | Adult Papillary Meningioma

United States
Beijing VDJBio Co., LTD.

Recruiting

A Study of Anti-IL-6R mAb Injection in Patients With iMCD

Idiopathic Multicentric Castleman's Disease

China
Shanghai Henlius Biotech

Suspended

Evaluate the Efficacy, Safety and Tolerability of HLX26 and Serplulimab in Patients With mCRC

Colorectal Cancer Metastatic

China
Jiangsu T-Mab Biopharma Co.,Ltd

Unknown

Safety Assessment of Repeated Administration of TK006 in Patients With Breast Cancer-related Bone Metastases

Breast Cancer
Jiangsu T-Mab Biopharma Co.,Ltd

Unknown

Assessment of TK006 in Patients With Breast Cancer-related Bone Metastases

Breast Cancer

China
Shanghai Henlius Biotech

Completed

Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 and HLX10 in Patients With Advanced/Metastatic Solid Tumor

Adult Solid Tumor

China
ThromboGenics

Completed

A Study to Evaluate the Safety and Efficacy of THR-317 for the Treatment of Diabetic Macular Oedema (DME)

Diabetic Retinopathy | Macular Edema

Czechia, Slovakia, Hungary
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Sintilimab for the Treatment of Locally Advanced, Metastatic, Recurrent, or Unresectable Undifferentiated Pleomorphic Sarcoma, SiARa Cancer Study

Metastatic Undifferentiated Pleomorphic Sarcoma | Recurrent Undifferentiated Pleomorphic Sarcoma | Locally Advanced Undifferentiated Pleomorphic Sarcoma | Unresectable Undifferentiated Pleomorphic Sarcoma

United States
The First Affiliated Hospital of Soochow University
The First Affiliated Hospital with Nanjing Medical University; The Affiliated... and other collaborators

Recruiting

Vedolizumab, Anti-CD25 Antibody, Rapid Reduction of Glucocorticoids for SR-aGVHD With Gastrointestinal Involvement

Safety and Efficacy

China
Jiangsu T-Mab Biopharma Co.,Ltd

Unknown

Assessment of Anti-RANKL Antibody in Post-menopausal Women

Osteoporosis

China
University Hospital, Brest

Completed

Lymphocyte and Cytokine Disturbances in Polymyalgia Rheumatica (TENOR-IMMUNO)

Polymyalgia Rheumatica

France
University of Washington
National Cancer Institute (NCI); National Center for Complementary and Integrative...

Completed

Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy

Stage IV Breast Cancer | Recurrent Breast Carcinoma | HER2/Neu Positive

United States
Shanghai Henlius Biotech

Recruiting

The Efficacy and Safety of HLX07 in Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC)

Cutaneous Squamous Cell Carcinoma

China
Gilead Sciences
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Study of Simtuzumab in HIV and/or Hepatitis C- Infected Adults With Liver Fibrosis

Hepatitis C | HIV | Liver Fibrosis | HIV/HCV Co-infection

United States
Shanghai Junshi Bioscience Co., Ltd.

Completed

A Single Dose Escalation Study of PCSK9 Inhibitor (JS002) in Health Subjects

Hypercholesterolemia

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies

Malignant Solid Neoplasm | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Malignant Solid Neoplasm | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate... and other conditions

United States
Shanghai Henlius Biotech

Not yet recruiting

HLX07(Anti-EGFR mAb) in Patients With Advanced or Metastatic Solid Tumors

Solid Tumor

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

Study of the SG001 Injection for Patients With Relapsed or Metastatic Uterine Cervical Cancer

Uterine Cervical Cancer

China

Search clinical trials for: Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Equatorial Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations